BEAM Beam Therapeutics

Beam Therapeutics Named to Boston Globe’s Top Places to Work List for 2022

Beam Therapeutics Named to Boston Globe’s Top Places to Work List for 2022

Beam Ranked No. 4 in Large Companies Category, Marking Fourth Consecutive Year as Top Workplace in Massachusetts

CAMBRIDGE, Mass., Dec. 02, 2022 (GLOBE NEWSWIRE) -- (Nasdaq: BEAM), a biotechnology company developing precision genetic medicines through base editing, today announced that the company has ranked No. 4 on the Boston Globe’s 2022 Top Places to Work in the “Large Companies” category, marking its fourth consecutive year as an honoree.

The Boston Globe’s , which will be featured in the print edition of Sunday’s paper, recognizes the most admired workplaces in the state, voted on by the people who know them best – their employees. The survey measures employee opinions about their company's leadership, appreciation, benefits and more. The winners are divided into four categories based on the number of employees: small (50-99); medium (100-249); large (250-999); and largest (1,000 or more). More than 94,000 employees at 381 companies completed surveys this year—a record high.

“At Beam, our vision is to provide life-long cures for patients suffering from serious diseases, and the ‘Beam Team’ is not only committed to making breakthroughs happen; they are committed to making Beam an exciting place to work, motivating colleagues and building a strong company culture in the process,” Susan O’Connor, chief human resource officer at Beam. “We are proud to be named, for the fourth year in a row, to this prestigious list of companies is Massachusetts who are committed to their missions, and importantly, each other.”

As an employer of choice, Beam is committed to fostering a culture that encourages employees to engage with colleagues. The company’s culture team frequently hosts programs on wellness, community engagement, diversity and inclusion, and team building to inspire, educate and care for employees. Events like Beam’s annual summer party, various walks and events in support of patient advocacy groups (including Light the Night and Walk with the Stars) and its “Balance @ Beam” wellness program supporting mental and financial health, demonstrate the company’s commitment to creating a culture that allows employees to thrive. Beam’s extensive benefits package includes programs like its "Take It as You Need It" paid time off policy, a five-week paid sabbatical after five years with an additional $5,000 stipend, medical benefits, a health and fitness reimbursement, 401k retirement plan, commuter reimbursement, family-forming benefits, an employee referral program and student loan refinancing.

In addition to its recognition as one of the Top Places to Work, Beam was named to the 2022 Best Places to Work list by the Boston Business Journal. For more information on careers at Beam, please visit .

About Beam Therapeutics

Beam Therapeutics (Nasdaq: BEAM) is a biotechnology company committed to establishing the leading, fully integrated platform for precision genetic medicines. To achieve this vision, Beam has assembled a platform that includes a suite of gene editing and delivery technologies and is in the process of building internal manufacturing capabilities. Beam’s suite of gene editing technologies is anchored by base editing, a proprietary technology that is designed to enable precise, predictable and efficient single base changes, at targeted genomic sequences, without making double-stranded breaks in the DNA. This has the potential to enable a wide range of potential therapeutic editing strategies that Beam is using to advance a diversified portfolio of base editing programs. Beam is a values-driven organization committed to its people, cutting-edge science, and a vision of providing life-long cures to patients suffering from serious diseases.

Contacts:

Investors:

Chelcie Lister

THRUST Strategic Communications

Media:

Dan Budwick

1AB



EN
02/12/2022

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Beam Therapeutics

 PRESS RELEASE

Beam Therapeutics Announces Publication of BEACON Phase 1/2 Data for r...

Beam Therapeutics Announces Publication of BEACON Phase 1/2 Data for risto-cel in Patients with Sickle Cell Disease (SCD) in The New England Journal of Medicine Prestigious Publication Reinforces risto-cel’s Durable, Differentiated Clinical Data for the Treatment of SCD with Severe Vaso-occlusive Crises (VOCs) Initially Presented at ASH, Data from 31 Patients with SCD Demonstrated Deep Resolution of Red Blood Cell Dysfunction and Reduced Time in Hospital Driven by a Median of One Cell Collection Cycle and Rapid Engraftment U.S. Biologics License Application (BLA) Submission for risto-...

Wedbush Research
  • Wedbush Research
UBI UBISOFT ENTERTAINMENT SA
XNCR XENCOR INC.
XENE XENON PHARMACEUTICALS INC
WDC WESTERN DIGITAL CORPORATION
VYGR VOYAGER THERAPEUTICS INC.
TTWO TAKE-TWO INTERACTIVE SOFTWARE INC.
SIMON SILICON MOTION TECHNOLOGY CORPORATION SPONSORED ADR
RARE ULTRAGENYX PHARMACEUTICAL INC.
PSTG PURE STORAGE INC. CLASS A
NVDA NVIDIA CORPORATION
NVCR NOVOCURE LTD.
NTAP NETAPP INC.
NKTR NEKTAR THERAPEUTICS
NBIX NEUROCRINE BIOSCIENCES INC.
MU MICRON TECHNOLOGY INC.
KURA KURA ONCOLOGY INC.
INTC INTEL CORPORATION
GOOGL ALPHABET INC. CLASS A
GERN GERON CORP.
FB FACEBOOK INC. CLASS A
FATE FATE THERAPEUTICS INC
CTMX CYTOMX THERAPEUTICS INC.
BMRN BIOMARIN PHARMACEUTICAL INC.
BIIB BIOGEN INC.
BCRX BIOCRYST PHARMACEUTICALS INC.
AXTI AXT INC.
ASND ASCENDIS PHARMA A/S SPONSORED ADR
ARDX ARDELYX INC
ACRS ACLARIS THERAPEUTICS INC.
CDR CD PROJEKT S.A.
FRX_CN FENNEC PHARMACEUTICALS
7974 NINTENDO CO. LTD.
2303 UNITED MICROELECTRONICS CORP.
EA ELECTRONIC ARTS INC.
ANAB ANAPTYSBIO INC.
ARGX ARGENX ADS
OVID OVID THERAPEUTICS
ISR ISORAY
AMZN AMAZON.COM INC.
AMD ADVANCED MICRO DEVICES INC.
AAPL APPLE INC.
MSFT MICROSOFT CORPORATION
APLS APELLIS PHARMACEUTICALS
DNLI DENALI THERAPEUTICS INC
RCUS ARCUS BIOSCIENCES
SRRK SCHOLAR ROCK HOLDING CORPORATION
KNSA KINIKSA PHARMACEUTICALS
REPL REPLIMUNE GROUP
ARVN ARVINAS HOLDING
STRO SUTRO BIOPHARMA
UBER UBER TECHNOLOGIES INC.
STOK STOKE THERAPEUTICS
SMCI SUPER MICRO COMPUTER
IDYA INC.
PASG IDEAYA BIOSCIENCES
BDTX PASSAGE BIO
ACET BLACK DIAMOND THERAPEUTICS
KROS ADICET BIO INC
ORIC KEROS THERAPEUTICS
ZNTL ORIC PHARMACEUTICALS
BEAM ZENTALIS PHARMACEUTICALS
LRMR BEAM THERAPEUTICS
PRAX LARIMAR THERAPEUTICS INC
U PRAXIS PRECISION MEDICINES
TVTX UNITY SOFTWARE
VRDN TRAVERE THERAPEUTICS INC
SANA VIRIDIAN THERAPEUTICS INC
PLTK SANA BIOTECHNOLOGY
RBLX PLAYTIKA HOLDING
DAWN ROBLOX
STX DAY ONE BIOPHARMACEUTICALS INC
APP SEAGATE TECHNOLOGY HLDGS PLC
GFS APPLOVIN CORP
GMTX GLOBALFOUNDRIES INC
TYRA GEMINI THERAPEUTICS INC
PEPG TYRA BIOSCIENCES INC
EWTX PEPGEN INC
SLDB EDGEWISE THERAPEUTICS INC
DDI SOLID BIOSCIENCES INC
APGE DOUBLEDOWN INTERACTIVE CO LTD
EMBRAC B APOGEE THERAPEUTICS INC
DNTH EMBRACER GROUP AB
ORKA DIANTHUS THERAPEUTICS INC
BCAX ORUKA THERAPEUTICS INC
ZBIO BICARA THERAPEUTICS INC.
TLX ZENAS BIOPHARMA INC.
MAZE TELIX PHARMACEUTICALS LIMITED
JBIO MAZE THERAPEUTICS INC
IMA JADE BIOSCIENCES INC
IMAGENEBIO INC.
David Nierengarten ... (+8)
  • David Nierengarten
  • Dennis Pak
  • Geoffrey Von Der Ahe
  • Laura Chico
  • Martin Fan
  • Robert Driscoll
  • Thomas Yip
  • Yun Zhong
David Nierengarten ... (+3)
  • David Nierengarten
  • Dennis Pak
  • Martin Fan

ResearchPool Subscriptions

Get the most out of your insights

Get in touch